Study shows fixed-dose combination therapy effective in treating high blood pressure

The new, once daily, single-tablet combination of olmesartan medoxomil, an angiotensin II receptor blocker (ARB), and amlodipine besylate, a calcium channel blocker (CCB), not only enables physicians to achieve therapeutic blood pressure (BP) goals but also ensures a 24-hour BP control that may confer additional benefits to the patients. The olmesartan/amlodipine combination (Azoren®, Pfizer) was [...]